BioMarin Pharmaceutical Market Sentiment

BioMarin Pharmaceutical Inc

BMRNNASDAQ

$55.66

-1.78-3.1%

Últ. Act.: Nov 3, 4:00 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivo FinanzasSentimientoPropiedad Comparar Opciones Informe de acciones

PRO

¿Por qué se mueve?:BioMarin Pharmaceutical shares are trading lower after the company reported...

Ganancias: Los beneficios de Q3 2026 se publicaron el lun nov 2nd, después del cierre del mercado

Conferencia telefónica: La conferencia telefónica más reciente comenzó a las 4:30 p. m., hace 1 día

Haz clic para ver el webcast

BioMarin Pharmaceutical Market Sentiment - Benzinga

BioMarin Pharmaceutical Market Sentiment

Market sentiment signals for BioMarin Pharmaceutical (BMRN): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 6.3% short float

Options Flow▲ 0.39 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

34 analysts

Options Flow (P/C)

0.39

More calls — Bullish

5,793 calls · 2,277 puts

Avg Consensus PT

$89

+59.3%

Highest Price Target

$126

+126.4%

Piper Sandler

Lowest Price Target

$60

+7.8%

HC Wainwright & Co.

Short Interest

6.3%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Nov 3, 2026	Morgan Stanley	Matthew Harrison—	+113.8%	$122 → $119	Maintained	Overweight
Nov 3, 2026	Oppenheimer	Leland Gershell—	+68.9%	$97 → $94	Maintained	Outperform
Nov 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+7.8%	$60 → $60	Maintained	Neutral
Nov 3, 2026	RBC Capital	Luca Issi—	+7.8%	$62 → $60	Maintained	Sector Perform
Nov 3, 2026	Stifel	Paul Matteis—	+18.6%	$70 → $66	Maintained	Hold
Oct 21, 2026	Morgan Stanley	Matthew Harrison—	+119.2%	$124 → $122	Maintained	Overweight
Oct 20, 2026	JP Morgan	Jessica Fye—	+56.3%	$86 → $87	Maintained	Overweight
Oct 20, 2026	Cantor Fitzgerald	Olivia Brayer Saunders—	+54.5%	$86 → $86	Maintained	Overweight
Oct 15, 2026	UBS	Joon Lee—	+58.1%	$114 → $88	Assumes	Buy
Oct 14, 2026	Barclays	Eliana Merle—	+104.8%	$111 → $114	Maintained	Overweight
Sep 10, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+7.8%	$60 → $60	Maintained	Neutral
Sep 1, 2026	Piper Sandler	Allison Bratzel—	+61.7%	$88 → $90	Maintained	Overweight
Aug 31, 2026	Jefferies	Akash Tewari—	+88.6%	$104 → $105	Maintained	Buy
Aug 31, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+7.8%	$59 → $60	Maintained	Neutral
Aug 19, 2026	BMO Capital	David Lebowitz—	+76.1%	$98	Initiate	Outperform
Aug 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+6.0%	$60 → $59	Maintained	Neutral
Aug 17, 2026	Piper Sandler	Allison Bratzel—	+58.1%	$82 → $88	Maintained	Overweight
Aug 17, 2026	Barclays	Eliana Merle—	+99.4%	$105 → $111	Maintained	Overweight
Aug 10, 2026	Canaccord Genuity	Whitney Ijem—	+104.8%	$111 → $114	Maintained	Buy
Aug 7, 2026	Morgan Stanley	Matthew Harrison—	+122.8%	$119 → $124	Maintained	Overweight
Aug 7, 2026	Oppenheimer	Leland Gershell—	+74.3%	$95 → $97	Maintained	Outperform
Aug 7, 2026	HC Wainwright & Co.	Mitchell S. Kapoor—	+7.8%	$50 → $60	Maintained	Neutral
Jul 16, 2026	Citigroup	Eric Joseph—	+36.5%	$75 → $76	Maintained	Buy
Jul 7, 2026	RBC Capital	Luca Issi—	+11.4%	$66 → $62	Maintained	Sector Perform
May 22, 2026	Canaccord Genuity	Whitney Ijem—	+99.4%	$116 → $111	Maintained	Buy